Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
NCT ID: NCT04488978
Last Updated: 2022-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
440 participants
INTERVENTIONAL
2020-05-21
2021-11-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
NCT05475665
Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
NCT05476354
Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers
NCT05688085
Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers
NCT05688098
Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers
NCT05663073
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Irbesartan low/Amlodipine low
Irbesartan low \& Amlodipine low, once daily for 8 weeks
Irbesartan/Amlodipine
QID
Irbesartan low/Amlodipine high
Irbesartan low \& Amlodipine high, once daily for 8 weeks
Irbesartan/Amlodipine
QID
Irbesartan high/Amlodipine low
Irbesartan high \& Amlodipine low, once daily for 8 weeks
Irbesartan/Amlodipine
QID
Irbesartan high/Amlodipine high
Irbesartan high \& Amlodipine high, once daily for 8 weeks
Irbesartan/Amlodipine
QID
Amlodipine low
Amlodipine low, once daily for 8 weeks
Irbesartan/Amlodipine
QID
Amlodipine high
Amlodipine high, once daily for 8 weeks
Irbesartan/Amlodipine
QID
Irbesartan low
Irbesartan low, once daily for 8 weeks
Irbesartan/Amlodipine
QID
Irbesartan high
Irbesartan high, once daily for 8 weeks
Irbesartan/Amlodipine
QID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Irbesartan/Amlodipine
QID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent
* Patients with Essential Hypertension
* Other inclusion applied
Exclusion Criteria
* Other exclusion applied
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Handok Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yonsei University Health System, Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI-C201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.